News

LAT Pharma brings a promising new therapeutic opportunity to NanoAntibiotics. Earlier this year LAT Pharma met with the FDA to discuss a submission for a novel therapy to

The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022. In December 2015, the Company

This will expand the original partnership agreement signed on April 2015, from four to five products, and adds a separate agreement which allows Vitruvias to buy in to

The companies will target several G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. The deal will see Heptares apply its StaR platform for the creation of

Labeling negotiations are now underway. The FDA extended the original action date of 17 January twice to enable for complete review. Sustol’s long-acting formulation is based on Heron’s

The designation was based on data from the ongoing Phase Ib Keynote-013 and Phase II Keynote-087 studies evaluating the drug as a single agent in patients with cHL,

The addition of Crelux provides augmented scientific depth and complements existing capabilities within the WuXi structure-based drug discovery platform. Crelux was founded in 2005 and has its laboratories

Both studies met their primary endpoints of non-inferiority to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300 mg based on the percentage of patients with HBV DNA levels below

A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016. Marinus Pharmaceuticals CEO Christopher